オカザキ　ケン   OKAZAKI Ken   岡崎　賢    所属   医学部 医学科（東京女子医科大学病院）    職種   教授・基幹分野長
論文種別	症例報告
言語種別	英語
査読の有無	査読あり
表題	Managing delayed union of fragility fractures of the pelvis successfully using romosozumab: A case report.
掲載誌名	正式名：Trauma case reports 略　 称：Trauma Case Rep ISSNコード：23526440/23526440
掲載区分	国外
巻・号・頁	57,pp.101176
著者・共著者	K Wada, A Tominaga, M Naruo, K Okazaki
担当区分	最終著者
発行年月	2025/05
概要	Fragility fractures of the pelvis (FFPs) are typically caused by minor trauma or without any trauma in older individuals with osteoporosis. In recent years, FFP incidence has increased considerably owing to the increasing number of individuals in the aging population as well as impaired daily life. Surgeries are the main treatment options for some types of FFPs; however, the potential of the use of romosozumab, an FDA-approved humanized monoclonal antibody that can bind and inhibit sclerostin, is yet to be evaluated. Romosozumab substantially increases bone mineral density (BMD) in the spine and the hip, improves bone strength, and prevents the occurrence of new fractures. Previous studies have demonstrated the efficacy of romosozumab in promoting fracture healing, including the healing of nonunion in some fractures. Herein, we present a case of a 61-year-old woman who had FFP delayed union, after falling 4 months before visiting our hospital. She presented with bilateral buttock and leg pain. Baseline BMD measured using dual-energy X-ray absorptiometry revealed a T-score of -3.8 and -3.2 for the lumbar spine and total hip, respectively. As the patient's BMD indicated a high risk of fractures, romosozumab was administered. Her pain improved 3 months after the medication. Computed tomography taken after 3 months revealed that the fracture had healed, suggesting that romosozumab is an effective medication for treating FFP delayed union and nonunion.
DOI	10.1016/j.tcr.2025.101176
PMID	40291407